Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duratio...
Guardado en:
Autores principales: | Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. de Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet, Upinder Singh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5fbb6d030f594c858730d7fccbf367da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Jingfeng Bi, et al.
Publicado: (2017) -
Parallels between pathogens and gluten peptides in celiac sprue.
por: Michael T Bethune, et al.
Publicado: (2008) - Lambda book report
-
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
por: Liu CH, et al.
Publicado: (2014) -
Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
por: Pizarro,Carolina, et al.
Publicado: (2011)